The Protocol – Get Busy Living (2022)

Other · Joe Tippens · March 24, 2022

Joe Tippens, 2022-03-24: Tippens's protocol page, dated March 24 2022, replaces his earlier CBD/Theracurmin stack with a commercial three-pathway supplement line ('Onco Adjunct') sold by a company he names as the manufacturer, and states he receives no payment and owns no stock in it.

I will not receive any financial remuneration from this company for the sale of these products and I do not own any stock of the company.

Joe Tippens, 2022-03-24: Tippens's protocol page, dated March 24 2022, replaces his earlier CBD/Theracurmin stack with a commercial three-pathway supplement line ('Onco Adjunct') sold by a company he names as the manufacturer, and states he receives no payment and owns no stock in it. C1 Tippens. Disclosure recorded neutrally: Tippens states no financial remuneration and no stock ownership; the page nevertheless promotes named commercial products (Onco Adjunct Pathway 1-4) alongside fenbendazole. Shows the protocol changed over time: the 2017 stack (CBD, Theracurmin, vitamin E) is gone and vitamin E was already dropped in the July 2020 note. Study type: other.